RxDoctor Payments Data

Julie Laird

Gerontology · Dothan, ALNPI 1427676584

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Mimedx Group, Inc. at 40.3% of the total. 2025 is the largest year on record at $250, more than ten times the $20 reported in 2022.

$674in general payments, 2019–2025

Across 30 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mimedx Group, Inc.$271
  • Paratek Pharmaceuticals, Inc.$138
  • Smith+Nephew$123
  • Ossur Americas, Inc.$42
  • Kowa Pharmaceuticals America, Inc.$36
  • Hartmann USA, Inc.$22
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$674100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$674 in reported general payments places this provider in the 55th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$1,739,856
Medicare patients
109
Services billed
8,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate25$196,923
Tobramycin Sulfate30$57,883
Flucytosine13$11,131
SantylCollagenase Clostridium Hist.20$10,375
Daptomycin40$7,243
ErtapenemErtapenem Sodium23$5,295
Meropenem24$2,349
Minocycline Hcl32$2,028
Clindamycin Hcl31$1,658
Levofloxacin131$928
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav39$786
Fluconazole43$265
Sodium Chloride0.9 % Sodium Chloride35$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$138$196,92325 claims
Smith+NephewSantyl$123$10,37520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 143 gerontology providers in Alabama.

Other gerontology in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →